


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A compound of formula (1):



wherein

Het is a bicyclic fused ring heteroaromatic group;

g is zero or the integer 1, 2, 3 or 4;

Each R^{16} , which may be the same or different, is an atom or group $-L^3(Alk^2)_tL^4(R^4)_u$,

L^3 and L^4 , which may be the same or different, are each a covalent bond or a linker atom or group $-O-$, $-S-$, $-C(O)-$, $-C(O)O-$, $-OC(O)-$, $-C(S)-$, $-S(O)-$, $-S(O)_2-$, $-N(R^8)-$, $-N(R^8)O-$, $-N(R^8)N-$, $-CON(R^8)-$, $-OC(O)N(R^8)-$, $-CSN(R^8)-$, $-N(R^8)CO-$, $-N(R^8)C(O)O-$, $-N(R^8)CS-$, $-S(O)_2N(R^8)-$, $-N(R^8)S(O)_2-$, $-N(R^8)CON(R^8)-$, $-N(R^8)CSN(R^8)-$, or $-N(R^8)SO_2N(R^8)-$,

R^8 is a hydrogen atom or an optionally substituted C_{1-6} alkyl group,

t is zero or the integer 1,

u is an integer 1, 2 or 3,

Alk^2 is an aliphatic or heteroaliphatic chain, and

R^4 is a hydrogen or halogen atom or a group selected from an optionally substituted C_{1-6} alkyl or C_{3-8} cycloalkyl group, $-OR^5$ (where R^5 is a hydrogen atom, an optionally


substituted C₁₋₆alkyl or C₃₋₈ cycloalkyl group), -SR⁵, -NR⁵R⁶ (where R⁶ is as just defined for R⁵ and may be the same or different), -NO₂, -CN, -CO₂R⁵, -SO₃H, -SOR⁵, SO₂R⁵, -SO₃R⁵, -OCO₂R⁵, -CONR⁵R⁶, -OCONR⁵R⁶, -CSNR⁵R⁶, -COR⁵, -OCOR⁵, -N(R⁵)COR⁶, -N(R⁵)CSR⁶, -SO₂N(R⁵)(R⁶), -N(R⁵)SO₂R⁶, N(R⁵)CON(R⁶)(R⁷) (where R⁷ is a hydrogen atom, an optionally substituted C₁₋₆alkyl or C₃₋₈cycloalkyl group), -N(R⁵)CSN(R⁶)(R⁷) or -N(R⁵)SO₂N(R⁶)(R⁷),

provided that when t is zero and each of L³ and L⁴ is a covalent bond then u is the integer 1 and R⁴ is other than a hydrogen atom;

L² is a covalent bond or an atom or group -O-, -S-, -C(O)-, -C(S)-, -S(O)-, -S(O)₂, -N(R⁸)- or -C(R⁸)(R^{8a})- (where R^{8a} is an atom or group as defined for R⁸ and may be the same or different);

Ar² is an optionally substituted aromatic or heteroaromatic group;

Alk is a chain



in which R is a carboxylic acid (-CO₂H), a carboxylic acid ester, a carboxylic acid amide, or a carboxylic acid biostere;

R¹ is a hydrogen atom or a C₁₋₆alkyl group;

L¹ is a covalent bond or a linker atom or group -O-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -C(S)-, -S(O)-, -S(O)₂-, -N(R⁸)-, -N(R⁸)O-, -N(R⁸)N-, -CON(R⁸)-, -OC(O)N(R⁸)-, -CSN(R⁸)-, -N(R⁸)CO-, -N(R⁸)C(O)O-, -N(R⁸)CS-, -S(O)₂N(R⁸)-, -N(R⁸)S(O)₂-, -N(R⁸)CON(R⁸)-, -N(R⁸)CSN(R⁸)-, or -N(R⁸)SO₂N(R⁸)-;

Alk¹ is an optionally substituted aliphatic chain;

DOCKET NO.: CELL-0113
Application No.: 09/899,488
Office Action Dated: August 7, 2003

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

n is zero or the integer 1;

R^2 is a hydrogen atom or an optionally substituted heteroaliphatic, ~~C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkenyl, C₃₋₁₀heterocycloalkyl, C₃₋₁₀heterocycloalkenyl, C₇₋₁₀bicycloalkyl, C₇₋₁₀tricycloalkyl, C₇₋₁₀bicycloalkenyl, C₇₋₁₀tricycloalkenyl, C₇₋₁₀bicycloheteroalkyl, C₇₋₁₀tricycloheteroalkyl, C₇₋₁₀bicycloheteroalkenyl, C₇₋₁₀tricycloheteroalkenyl, C₃₋₁₀cycloaliphatic, C₃₋₁₀heterocycloaliphatic, C₇₋₁₀polycycloaliphatic, C₇₋₁₀heteropolycycloaliphatic~~, aromatic or heteroaromatic group, wherein said heteroaliphatic, heterocycloalkyl, heterocycloalkenyl, bicycloheteroalkyl, tricycloheteroalkyl, bicycloheteroalkenyl and tricycloheteroalkenyl ~~C₃₋₁₀heterocycloaliphatic, and C₇₋₁₀heteropolycycloaliphatic~~ groups contain one, two, three, or four heteroatoms or heteroatom-containing groups as defined for L³ and L⁴, which may be the same or different;

provided that Het is not a 2,6-naphthyridin-1-yl, isoquinolin-1-yl, 2,7-naphthyridin-1-yl or quinazolin-4-yl group;

and the salts and N-oxides thereof.

2. (original) A compound according to Claim 1 in which Alk is a chain




3. (original) A compound according to Claim 1 in which R is a carboxylic acid (-CO₂H) group.

DOCKET NO.: CELL-0113
Application No.: 09/899,488
Office Action Dated: August 7, 2003

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

4. (original) A compound according to Claim 1 in which R is an esterified carboxyl group of formula $\text{-CO}_2\text{Alk}^7$.
5. (original) A compound according to Claim 1 in which R^1 is a hydrogen atom.
6. (original) A compound according to Claim 1 in which Ar^2 is an optionally substituted phenylene group.
7. (original) A compound according to Claim 1 in which L^1 is a $\text{-N(R}^8\text{)-}$ group where R^8 is a hydrogen atom or an optionally substituted C_{1-6} alkyl group.
8. (original) A compound according to Claim 7 in which R^8 is a methyl, ethyl, or n-propyl group.
9. (original) A compound according to Claim 1 in which L^1 is a covalent bond.
10. (original) A compound according to Claim 1 in which n is the integer 1, Alk^1 is an optionally substituted straight or branched C_{1-6} alkylene chain and R^2 is a hydrogen atom.
11. (original) A compound according to Claim 10 in which Alk^1 is a $\text{-CH}_2\text{-}$, $\text{-CH}_2\text{CH}_2\text{-}$, $\text{-CH}_2\text{CH}_2\text{CH}_2\text{-}$, $\text{-CH(CH}_3\text{)CH}_2\text{-}$ or $\text{-C(CH}_3\text{)}_2\text{CH}_2\text{-}$ chain.


12. (currently amended) A compound according to Claim 1 in which L^1 is a covalent bond, n is zero and R^2 is an optionally substituted ~~C_{5-7} heterocycloalkyl or C_{5-7} heterocycloalkenyl~~ C_{5-7} heterocycloaliphatic group.
13. (original) A compound according to Claim 12 in which R^2 is an optionally substituted piperidinyl, homopiperidinyl, heptamethyleneiminyl, pyrrolidinyl, piperazinyl, homopiperazinyl, morpholinyl or thiomorpholinyl group.
14. (original) A compound according to Claim 1 in which L^2 is an -O- atom or -N(R^8)- group in which R^8 is a hydrogen atom or an optionally substituted C_{1-6} alkyl group.
15. (previously presented) A compound according to Claim 1 of formula (2a):



wherein:

- R^{17} is an atom or group R^{16} as previously defined;
 h is zero or the integer 1, 2 or 3;
 R^{18} is a hydrogen atom or an atom or group R^{16} as previously defined;
and the salts and N-oxides thereof.

16. (previously presented) A compound according to Claim 1 of formula (2b):



wherein:

X, Y and Z are each independently selected from a nitrogen, oxygen or sulphur atom or CH group;

the broken line (---) represents saturation or unsaturation;

and the salts and N-oxides thereof.

17. (original) A compound according to Claim 16 in which X is an O or S atom, Y and Z are each a group CH, a single bond joins X and Y and a double bond joins Y and Z.

18. (currently amended) A compound according to Claim 16 in which Z is an O or S atom, X and Y is are each a CH group, a single bond joins Y and Z and a double bond joins X and Y.

19. (previously presented) A compound which is:

S-2- {[2-Dipropylamino)-3,4-dioxo-1-cyclobutenyl]amino}-3- {4-[(1-methylbenzimidazol-2-yl)amino]phenyl} propanoic acid;

S-2- {[2-Dipropylamino)-3,4-dioxo-1-cyclobutenyl]amino}-3- {4-[(1-methylbenzimidazol-2-yl)amino]phenyl} propanoic acid;

DOCKET NO.: CELL-0113
Application No.: 09/899,488
Office Action Dated: August 7, 2003

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

S-2-{{2-(2-Methylpiperidin-1-yl)-3,4-dioxo-1-cyclobutenyl}amino}-3-{4-[(1-methylbenzimidazol-2-yl)amino]phenyl}propanoic acid;

(S)-3-[4-(Thiophen[2,3-d]pyrimidin-4-ylamino)phenyl]2-(2-(diethylamino-3,4-dioxocyclobut-1-enylamino)propanoic acid;

and the salts, N-oxides and carboxylic acid esters thereof.

495/04
31/519

20. (original) A pharmaceutical composition comprising a compound according to Claim 1 together with one or more pharmaceutically acceptable carriers, excipients or diluents.

21. (previously presented) A method for the treatment of inflammatory arthritis, allograft rejection, diabetes, inflammatory dermatoses, asthma or inflammatory bowel disease comprising administering to a mammal suffering from such a disease or disorder a therapeutically effective amount of a compound according to Claim 1.

22. (canceled)

23. (previously presented) A method according to Claim 21 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, vasculitis and polydermatomyositis.

19/02

24. (previously presented) A method according to Claim 21 wherein said inflammatory dermatoses are selected from the group consisting of psoriasis and dermatitis.

DOCKET NO.: CELL-0113
Application No.: 09/899,488
Office Action Dated: August 7, 2003

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

25. (canceled)

26. (canceled)

27. (previously presented) A compound according to claim 19 wherein the carboxylic acid esters are selected from the group consisting of methyl, ethyl, propyl, and i-propyl.

Filing Date

7/5/01

9
10/ R99,461

Paper

#

~~8~~ 8 ~~1/6/03~~
11 - 6/4/03

Title

✓

Abstract

✓

Oath

✓

Priority

~~UK~~ UK

Application

0016775
0024364.8

filed

7/2/00

11/21/00

IDS

#

3 #7

Drawings

None

Number of claims

25, 26

twenty-five four

CMPD

1-19

COMP

20

USE

22-26

PREP

21, 23, 24

514/

540/

544/

546/

548/

549/

367	300	243	259.7	182	235	278	119	141	180
371	301	244	260.1	183	236	279	115	177	217
379	302	249	261.1	184	237	280	116		211
397	303	250	262.1		238	281	117		309.7
403	304	251	263.1		239	282	121		362.5
412	305	252	264.1		240	283	122		503
418	306	253	265.1		241		123		453
	307	254	266.1		242		133		
	308	255	267.1		243		134		
	309	256	268.1		244		135		
	310	257	269.1		245		136		
	311	258	270.1		246		137		
	312	259	271.1		247		138		
	313	260	272.1		248		139		
	314	261	273.1		249		140		
	315	262	274.1		250		141		
	316	263	275.1		251		142		
	317	264	276.1		252		143		
	318	265	277.1		253		144		
	319	266	278.1		254		145		
	320	267	279.1		255		146		
	321	268	280.1		256		147		
	322	269	281.1		257		148		
	323	270	282.1		258		149		
	324	271	283.1		259		150		
	325	272	284.1		260		151		
	326	273	285.1		261		152		
	327	274	286.1		262		153		
	328	275	287.1		263		154		
	329	276	288.1		264		155		
	330	277	289.1		265		156		
	331	278	290.1		266		157		
	332	279	291.1		267		158		
	333	280	292.1		268		159		
	334	281	293.1		269		160		
	335	282	294.1		270		161		
	336	283	295.1		271		162		
	337	284	296.1		272		163		
	338	285	297.1		273		164		
	339	286	298.1		274		165		
	340	287	299.1		275		166		
	341	288	300.1		276		167		
	342	289	301.1		277		168		
	343	290	302.1		278		169		
	344	291	303.1		279		170		
	345	292	304.1		280		171		
	346	293	305.1		281		172		
	347	294	306.1		282		173		
	348	295	307.1		283		174		
	349	296	308.1		284		175		
	350	297	309.1		285		176		
	351	298	310.1		286		177		
	352	299	311.1		287		178		
	353	300	312.1		288		179		
	354	301	313.1		289		180		
	355	302	314.1		290		181		
	356	303	315.1		291		182		
	357	304	316.1		292		183		
	358	305	317.1		293		184		
	359	306	318.1		294		185		
	360	307	319.1		295		186		
	361	308	320.1		296		187		
	362	309	321.1		297		188		
	363	310	322.1		298		189		
	364	311	323.1		299		190		
	365	312	324.1		300		191		
	366	313	325.1		301		192		
	367	314	326.1		302		193		
	368	315	327.1		303		194		
	369	316	328.1		304		195		
	370	317	329.1		305		196		
	371	318	330.1		306		197		
	372	319	331.1		307		198		
	373	320	332.1		308		199		
	374	321	333.1		309		200		
	375	322	334.1		310		201		
	376	323	335.1		311		202		
	377	324	336.1		312		203		
	378	325	337.1		313		204		
	379	326	338.1		314		205		
	380	327	339.1		315		206		
	381	328	340.1		316		207		
	382	329	341.1		317		208		
	383	330	342.1		318		209		
	384	331	343.1		319		210		
	385	332	344.1		320		211		
	386	333	345.1		321		212		
	387	334	346.1		322		213		
	388	335	347.1		323		214		
	389	336	348.1		324		215		
	390	337	349.1		325		216		
	391	338	350.1		326		217		
	392	339	351.1		327		218		
	393	340	352.1		328		219		
	394	341	353.1		329		220		
	395	342	354.1		330		221		
	396	343	355.1		331		222		
	397	344	356.1		332		223		
	398	345	357.1		333		224		
	399	346	358.1		334		225		
	400	347	359.1		335		226		
	401	348	360.1		336		227		
	402	349	361.1		337		228		
	403	350	362.1		338		229		
	404	351	363.1		339		230		
	405	352	364.1		340		231		
	406	353	365.1		341		232		
	407	354	366.1		342		233		
	408	355	367.1		343		234		
	409	356	368.1		344		235		
	410	357	369.1		345		236		
	411	358	370.1		346		237		
	412	359	371.1		347		238		
	413	360	372.1		348		239		
	414	361	373.1		349		240		
	415	362	374.1		350		241		
	416	363	375.1		351		242		
	417	364	376.1		352		243		
	418	365	377.1		353		244		
	419	366	378.1		354		245		
	420	367	379.1		355		246		
	421	368	380.1		356		247		
	422	369	381.1		357		248		
	423	370	382.1		358		249		
	424	371	383.1		359		250		
	425	372	384.1		360		251		
	426	373	385.1		361		252		
	427	374	386.1		362		253		
	428	375	387.1		363		254		
	429	376	388.1		364		255		
	430	377	389.1		365		256		
	431	378	390.1		366		257		
	432	379	391.1		367		258		
	433	380	392.1		368		259		
	434	381	393.1		369		260		
	435	382	394.1		370		261		
	436	383	395.1		371		262		
	437	384	396.1		372		263		
	438	385	397.1		373		264		
	439	386	398.1		374		265		
	440	387	399.1		375		266		
	441	388	400.1		376		267		
	442	389	401.1		377		268		
	443	390	402.1		378		269		
	444	391	403.1		379		270		
	445	392	404.1		380		271		
	446	393	405.1		381		272		
	447	394	406.1		382		273		
	448	395	407.1		383		274		
	449	396	408.1		384		275		
	450	397	409.1		385		276		
	451	398	410.1		386		277		
	452	399	411.1		387		278		
	453	400	412.1		388		279		
	454	401	413.1		389		280		
	455	402	414.1		390		281		
	456	403	415.1		391		282		
	457	404	416.1		392		283		
	458	405	417.1		393		284		
	459	406	418.1		394		285		
	460	407	419.1		395		286		
	461	408	420.1		396		287		
	462	409	421.1						